Mechanistic studies on long peptide based vaccins for the use in
cancer therapy.
Bijker, M.S.
Citation
Bijker, M. S. (2007, November 1). Mechanistic studies on long peptide based vaccins for
the use in cancer therapy. Retrieved from https://hdl.handle.net/1887/12430
Version: Corrected Publisher’s Version
License: Licence agreement concerning inclusion of doctoral thesis in the
Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/12430
Note: To cite this publication please use the final published version (if applicable).
1
Mechanistic studies on long
peptide-based vaccines
for the use in cancer therapy
2
3
Mechanistic studies on long
peptide-based vaccines
for the use in cancer therapy
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus Prof. Mr. P. F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 1 november 2007
klokke 16:15
door
Martijn Sander Bijker
geboren te Lisse
in 1978
4
PROMOTIECOMMISSIE:
Promotor: Prof. Dr. C. J. M. Melief Co-promotores: Dr. S. H. van der Burg Dr. R. Offringa
Referent: Dr. J. B. Haanen (NKI/AVL, Amsterdam) Overige leden: Prof. Dr. E. Goulmy
Prof. Dr. G. G. Kenter
Prof. Dr. J. P. Medema (AMC, Amsterdam) Prof. Dr. T. H. Ottenhoff
Prof. Dr. E. J. H. J. Wiertz
© Martijn S. Bijker, 2007 ISBN: 9789064641824
Printed by: Ponsen & Looijen BV
Cover: Top view of a MHC class I molecule with the OVA257-264 peptide in the peptide binding groove. Picture has been made by Drs. Wouter Pos with the use of the program ´pymol´ and data from Fremont et al., PNAS 1995 .
Niets uit deze uitgave mag verveelvoudigd en/of openbaar gemaakt worden zonder voorafgaande schriftelijke toestemming van de auteur. No part of this thesis may be reproduced in any form without written permission from the author.
The research described in this thesis was conducted at the Department of Immunohematology and Bloodtransfusion at the Leiden University Medical Center and was financially supported by the Dutch Cancer Society (KWF kanker bestrijding).
Financial support for the publication of this thesis was provided by:
Gerard en Joke Fasseur, the Dutch Cancer Society, ISA Pharmaceuticals BV, J. E. Jurriaanse Stichting, Greiner Bio-One, BD Bioscience, Clean Air techniek BV, Beckman Coulter Nederland BV, Cambrex Bio Science Verviers, Tebu-bio, and Corning BV.
5
In the long run
the pessimist
may be right,
but the optimist
has a better
time on the trip.
Daniel L. Reardon
6
7
Contents
1 General introduction. 9
2 CD8+ T cell tolerance.
CD8+ T cell priming by exact peptide-epitopes in Incomplete Freund’s Adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.
Journal of Immunology. 2007 Oct15;179(8):5033-40
27
3 Pharmacokinetics of short and long peptide-based vaccines.
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
(submitted)
49
4 Dendritic cell activating agonists.
Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists.
Vaccine. 2007 Feb 9;25(8):1379-89
69
5 Toll-like receptors conjugated to peptides.
TLR Ligand-peptide conjugates efficiently prime CD8+ T-lymphocytes by Joined Entry of TLR-Ligand and Antigen in Dendritic Cells.
Journal of Biological Chemistry. 2007 July 20; 282(29): 21145-21159
93
6 Cbl-b and anti-tumor immunity.
Spontaneous tumor rejection by cbl-b deficient CD8+ T cells.
Journal of Experimental Medicine. 2007 Apr 16;204(4):879-91
121
7 Design and development of synthetic peptide vaccines.
(Discussion).
Adapted from Expert Review of Vaccines. 2007 Aug;6(4):591-603
145
8 Nederlandse Samenvatting 171
9 Dankwoord 177
10 Curriculum vitae 181
11 Publication list 185
8
